A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that the ...

No significant increase in hazard ratios seen for GI events for semaglutide vs dulaglutide, tirzepatide vs dulaglutide, tirzepatide vs semaglutide. HealthDay News For patients with type 2 diabetes ...

A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid type 2 ...

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent ...

Risks for kidney failure and major cardiovascular events between three GLP-1 receptor agonists were similar among veterans with diabetes. Mortality risk and certain adverse events differed between the ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide further reduced risk for stroke vs. empagliflozin as treatment for diabetes. Dulaglutide’s impact on ...

Trials have shown that semaglutide can reduce major cardiovascular events, but the extent of tirzepatide’s heart protection ...

Please provide your email address to receive an email when new articles are posted on . Men who used dulaglutide, semaglutide or tirzepatide had a rise in free testosterone after starting treatment.

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of ...